亞洲 眼科
眼科藥：從乾眼、青光眼到視網膜疾病。
8追蹤資產
5已核准
這個賽道在做什麼
眼科涵蓋眼睛前段（乾眼、青光眼、近視）與後段（濕性黃斑部病變、糖尿病黃斑水腫、遺傳性視網膜疾病）。眼藥水與眼內注射在局部作用，臨床試驗規模通常比其他領域小；日本藥廠做出了好幾個全新機轉的青光眼藥。中國的康柏西普是最早一批本土研發的抗 VEGF 眼內注射藥，韓國與中國公司現在也把眼科新藥授權給海外夥伴。
階段分布
已核准5 5
第三期1 1
第二期2 2
國家分布
日本5 5
中國2 2
韓國1 1
資產表
| 排名 | 資產 | 國際非專利名稱 | 原研公司 | 國家 | 標的 | 機轉 | 最高階段 | 適應症 | 試驗登錄號 | 海外權利人 | 交易日期 | 首付款 | 總額上限 | 最新事件 | 最新事件日期 | 來源 | 來源日期 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Rebamipide ophthalmic (OPC-12759; Mucosta) | rebamipide | Otsuka Pharmaceutical Co., Ltd. | Japan | Ocular-surface mucin production (functional pathway; direct receptor Not disclosed) | Mucin-production promoting ophthalmic suspension | Approved — Japan (2011-09) | Dry eye disease | NCT01660256 | None reported | — | — | — | Confirmatory ophthalmic-solution study registry updated; completed | 2021-05-05 | 1 2 3 | 2021-05-05 |
| 2 | Conbercept (KH902; Lumitin / Langmu) | conbercept | Chengdu Kanghong Biotech Co., Ltd. (Kanghong Pharmaceutical Group) | China | VEGF-A; VEGF-B; PlGF | VEGF-receptor / Fc fusion-protein ligand trap | Approved — China (2013-11) | Neovascular AMD; myopic CNV; diabetic macular edema; retinal vein occlusion-associated macular edema | NCT03223714 | None reported | — | — | — | 2026 interim report confirms marketed conbercept and Phase 3 development of high-dose KH902-R10 | 2026-08-26 | 1 2 3 4 5 | 2026-08-26 |
| 3 | Ripasudil (K-115; Glanatec) | ripasudil | D. Western Therapeutics Institute, Inc. | Japan | Rho-associated protein kinase (ROCK) | ROCK inhibitor that promotes trabecular outflow | Approved — Japan (2014-09) | Glaucoma and ocular hypertension; Fuchs endothelial corneal dystrophy (K-321, investigational) | NCT06048380 | Kowa (worldwide rights including Japan) | 2002-09 | Not disclosed | Not disclosed | Company pipeline lists worldwide ripasudil licence and investigational FECD development | Not disclosed | 1 2 3 | Not disclosed |
| 4 | Omidenepag isopropyl (DE-117; Eybelis / Omlonti) | omidenepag isopropyl | UBE Corporation (formerly Ube Industries, Ltd.) | Japan | Prostaglandin EP2 receptor | Selective EP2 receptor agonist; promotes aqueous humor outflow | Approved — US (2022-09) | Primary open-angle glaucoma and ocular hypertension | NCT05279716 | Santen (worldwide development, manufacturing and commercialization rights) | 2011-10-14 | Not disclosed | Not disclosed | Santen and UBE announced FDA approval dated 2022-09-22 | 2022-09-26 | 1 2 3 | 2022-09-26 |
| 5 | Sepetaprost (ONO-9054 / DE-126 / STN1012600; Setaneo) | sepetaprost | Ono Pharmaceutical Co., Ltd. | Japan | Prostaglandin FP and EP3 receptors | Dual FP / EP3 receptor agonist prodrug | Approved — Japan (2025-08) | Glaucoma and ocular hypertension | jRCT2031220267 | Santen (exclusive worldwide rights) | 2016-03-30 | Not disclosed | Not disclosed | Setaneo launched in Japan after August approval | 2025-10-23 | 1 2 3 4 | 2025-10-23 |
| 6 | Tanfanercept (HL036) | tanfanercept | HanAll Biopharma Co., Ltd. (with Daewoong Pharmaceutical) | South Korea | Tumor necrosis factor (TNF) | Engineered soluble TNFR1 fragment that binds TNF | Phase 3 — US (2019-03); VELOS-4 registry suspended (updated 2024-05), company reports ongoing (2026-01) | Dry eye disease (investigational) | NCT03846453 | NCT06400589 | Harbour BioMed (Greater China; portfolio licence includes HL161 and HL036) | 2017-09-12 | Not disclosed (asset-specific) | Up to USD 81m (HL161 + HL036 portfolio; not allocated) | Company reported VELOS-4 ongoing; registry retains older suspended status due to logistical issue | 2026-01-21 | 1 2 3 4 5 6 | 2026-01-21 |
| 7 | H-1337 | Not disclosed | D. Western Therapeutics Institute, Inc. | Japan | Multiple protein kinases (specific target list Not disclosed) | Small-molecule multi-kinase inhibitor ophthalmic solution | Phase 2 — US (2023-08; Phase 2b completed) | Glaucoma and ocular hypertension (investigational) | NCT05913232 | None reported | — | — | — | Company pipeline confirms completed US Phase 2b and preparation for Phase 3 | Not disclosed | 1 2 3 | Not disclosed |
| 8 | KH631 | Not disclosed | Chengdu Origen Biotechnology Co., Ltd. (Kanghong) | China | VEGF pathway (anti-angiogenic gene therapy) | AAV-delivered anti-angiogenic gene therapy | Phase 2 — China (confirmed 2026-08); Phase 1 — US | Neovascular AMD (clinical); diabetic macular edema (China clinical trial permission, not a phase claim) | NCT05672121 | NCT05657301 | None reported | — | — | — | 2026 interim report lists China Phase 2 and US Phase 1 for nAMD | 2026-08-26 | 1 2 3 4 | 2026-08-26 |